@article{01GJPZTZ2TAGDTBJXGECAEHK91,
  abstract     = {{Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.}},
  articleno    = {{992137}},
  author       = {{Infante, Maria Stefania and Salmanton-García, Jon and Fernández-Cruz, Ana and Marchesi, Francesco and Jaksic, Ozren and Weinbergerová, Barbora and Besson, Caroline and Duarte, Rafael F. and Itri, Federico and Valković, Toni and Szotkovski, Tomáš and Busca, Alessandro and Guidetti, Anna and Glenthøj, Andreas and Collins, Graham P. and Bonuomo, Valentina and Sili, Uluhan and Seval, Guldane Cengiz and Machado, Marina and Cordoba, Raul and Blennow, Ola and Abu-Zeinah, Ghaith and Lamure, Sylvain and Kulasekararaj, Austin and Falces-Romero, Iker and Cattaneo, Chiara and Van Doesum, Jaap and Piukovics, Klára and Omrani, Ali S. and Magliano, Gabriele and Ledoux, Marie-Pierre and de Ramon, Cristina and Cabirta, Alba and Verga, Luisa and López-García, Alberto and Da Silva, Maria Gomes and Stojanoski, Zlate and Meers, Stef and Lahmer, Tobias and Martín-Pérez, Sonia and Dávila-Vals, Julio and Van Praet, Jens and Samarkos, Michail and Bilgin, Yavuz M. and Karlsson, Linda Katharina and Batinić, Josip and Nordlander, Anna and Schönlein, Martin and Hoenigl, Martin and Ráčil, Zdeněk and Mladenović, Miloš and Hanakova, Michaela and Zambrotta, Giovanni Paolo Maria and De Jonge, Nick and Adžić-Vukičević, Tatjana and Nunes-Rodrigues, Raquel and Prezioso, Lucia and Navrátil, Milan and Marchetti, Monia and Cuccaro, Annarosa and Calbacho, Maria and Giordano, Antonio and Cornely, Oliver A. and Hernández-Rivas, José-Ángel and Pagano, Livio}},
  issn         = {{2234-943X}},
  journal      = {{FRONTIERS IN ONCOLOGY}},
  keywords     = {{Cancer Research,Oncology,non-Hodgkin lymphoma (NHL),chronic lymphocytic leukemia (CLL),lymphoproliferative diseases (LPD),immune system COVID19,infection risk,targeted drugs,SARS-CoV-2}},
  language     = {{eng}},
  pages        = {{17}},
  publisher    = {{Frontiers Media SA}},
  title        = {{B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection : a European Hematology Association Survey (EPICOVIDEHA)}},
  url          = {{http://doi.org/10.3389/fonc.2022.992137}},
  volume       = {{12}},
  year         = {{2022}},
}

Altmetric

View in Altmetric

Web of Science

Times cited: